Drug Discovery Shifts Toward Rapid, Mass Screening

Ethnobotany, Ethnopharmacology and Drug Discovery

     This manuscript is a review of a number of ethnobotany and ethnopharmacology texts and papers in order to arrive at current understanding and scope of ethnobotany and ethnopharmacology. It includes either a brief definition of both fields and presenting some examples on them. Also it has a glimpse on the geographical coverage of research works throughout the world, important issue of prope...

Miniaturized screening technologies for drug discovery.

Adaptive Profiling (APL) and other biochip companies aim to harness the power of microsystems technology together with advances in chemistry and molecular biology, to become service and technology providers to organizations involved in pharmaceutical research and development. By supplying a unique range of decision-making tools that aid an earlier identification of qualified drug candidates for...

Phenotypic Drug Discovery with High Content Screening

Drug discovery in its early history used to be conducted mainly in a target-agnostic fashion, focusing on qualitative readouts from a living system -cells, tissue, or organisms -and asking the question, ‘Did this entity affect the phenotype?’. With the rise of molecular biology in the early 1980s and an ever more powerful genomics toolkit from the 1990s, there was a marked shift away from pheno...

ImprovIng ADmE ScrEEnIng proDuctIvIty In Drug DIScovEry

High Content Screening in Drug Discovery

The term high content screening (HCS) has become synonymous with imaging screen using automated microscopes and automated image analysis. The term was coined a little over 10 years ago, since then the technology evolved considerably and has established itself firmly in the drug discovery and development industry. Both the instruments and the software controlling the instruments and analyzing th...